CD200 and non-small cell lung carcinoma: CD200 was also shown to have a favorable role in non-small cell lung cancer (NSCLC) where higher levels of tumoral CD200 expression were correlated with significantly improved overall survival, recurrence-free survival, and cancer-specific survival relative to those with low tumoral CD200 expression [96].